Michael Varney comes out of brief Genentech 'retirement' for R&D gig at Erasca; Vivek Ramaswamy's Immunovant recruits J&J vet for CSO post
→ Michael Varney is opening up a new chapter in his career after stepping down recently from a high-profile job as head of research and early development at Roche’s prestigious gRED organization in South San Francisco.
He’s taken a job as chairman of R&D at Erasca, a private biotech company that recently raised a whopping $200 million from a syndicate led by ARCH and Cormorant. Erasca is led by Jonathan Lim, who sold Ignyta to Roche for $1.7 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.